ALS Worldwide welcomes any questions or comments you might have.  We provide free, personalized and confidential support services to anyone in the ALS community—whether you are a patient or a loved one, friend, health care professional or caregiver of someone diagnosed.

Get help now! Fill out the Online Profile Form or if you would prefer to talk with someone by email or phone first, please contact us at [email protected] or 1-608-663-0920.

For all other inquiries, please use the email form to the right and we will respond promptly to your request.Thank you.

ALS Worldwide
5808 Dawley Drive
Fitchburg, WI 53711‑7209

ALS Worldwide
Sorted by: July 2017 | View All
July 20, 2017

How to Qualify for Social Security Benefits With ALS

Did you know that an ALS diagnosis automatically qualifies for Social Security disability benefits? If you or a loved one has been diagnosed with ALS, you might be eligible for financial resources to help pay for medical bills, treatments, and any other daily living expense.

July 11, 2017


"Researchers have shown a drug engineered to combat the gene causing spinocerebellar ataxia type 2 (SCA2) might also be used to treat ALS. Two studies were published in the journal Nature with funding from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH).

July 10, 2017

More results are in! Edavone shown to provide greater benefits to ALS patients after one year

Data from the open-label extension trial of Edaravone (Radicava) in patients with ALS demonstrated the drug continued to provide benefits after 48 weeks of treatment. These findings were presented by researchers from MT Pharma America, the company which manufactures Edaravone, at the May 18-20 European Network for the Cure of ALS (ENCALS) Annual Meeting.

July 10, 2017

Who is in your village? We all need help to fight ALS/MND/ELA

It takes a village to care for someone with ALS. Unfortunately, caregivers and patients often find themselves isolated from the rest of the world.